Host: Darryl S. Chutka, M.D.

Guest: Aleksandra Kukla, M.D.

In 2023, an estimated 14% of all adults in the U.S. or just over 35 million individuals had chronic kidney disease and it’s even more common in the elderly population affecting over 1/3 of those over the age of 65. It represents the 8th leading cause of death in the U.S. It’s now known that chronic kidney disease is associated with systemic inflammation, which is responsible for a variety of complications including atherosclerosis and subsequent cardiovascular disease. Does kidney disease result in inflammation or does inflammation produce renal dysfunction? Are there inflammatory markers we could measure to assess this inflammation? Can we do anything to reduce the inflammation and if so, does it improve patient outcome? These are just some of the questions I’ll be asking my guest, Aleksandra Kukla, M.D., from the Division of Nephrology at the Mayo Clinic as we discuss “Chronic Kidney Disease as a Systemic Inflammatory Syndrome”.

These talks on Inflammation and Cardiometabolic Disease are sponsored by Novo Nordisk

Learn more about this series HERE

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Host: Darryl S. Chutka, M.D.

Guest: Maria L. Collazo-Clavell, M.D.

Its common knowledge that those who are obese are at greater risk for developing metabolic syndrome, diabetes and cardiovascular disease. However, the reason for this association has not always been clear. It does appear that systemic inflammation plays a major role and obesity triggers this inflammation. But what specifically initiates the inflammation? How can we measure it? Most importantly, can we reduce or eliminate this inflammation and prevent the progression to these cardiometabolic states? My guest for this podcast is Maria L. Collazo-Clavell, M.D., from the Division of Endocrinology and Metabolism at the Mayo Clinic and we’ll discuss “Inflammation and Cardiometabolic Disease: Obesity- The Linking Pathology”.

These talks on Inflammation and Cardiometabolic Disease are sponsored by Novo Nordisk

Learn more about this series HERE

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Host: Darryl S. Chutka, M.D. [@chutkaMD]

Guest: Alina M. Allen, M.D., M.S.

Fat deposits in the liver are quite common and many individuals have no idea they have the condition. A minority of those individuals will develop an associated hepatic inflammation. It’s not entirely clear why some progress to this state, although there are some known risk factors. Steatohepatitis is a potentially serious health problem and can lead to end-stage liver disease. It’s also associated with cardiovascular disease and all of its complications. The topic for today’s podcast is Hepatic Inflammation and Metabolic Dysfunction-Associated Steatohepatitis. My guest is Alina M. Allen, M.D., M.S., from the Division of Gastroenterology and Hepatology at the Mayo Clinic. What are the risk factors for this health problem? Should we be screening patients for its presence and how should it be managed. These are just some of the topics we’ll discuss in this podcast.

These talks on Inflammation and Cardiometabolic Disease are sponsored by Novo Nordisk

Learn more about this series HERE

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.